<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602899</url>
  </required_header>
  <id_info>
    <org_study_id>PINS-013</org_study_id>
    <nct_id>NCT02602899</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy</brief_title>
  <acronym>ANT-DBS-RE</acronym>
  <official_title>Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Pins Medical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Pins Medical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the long-term clinical effectiveness and safety of the PINS Deep Brain Stimulation
      to patients with refractory epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in seizure frequency from baseline to the seizure count evaluation period 6 month</measure>
    <time_frame>6 month of stimulation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in seizure frequency from baseline to the seizure count evaluation period</measure>
    <time_frame>1,3,6,12 months of stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Quality of Life in Epilepsy-31 (QOLIE-31) Score in Patients With Baseline &amp; at Least One Post-baseline QOLIE Assessment</measure>
    <time_frame>Mean change from baseline QOLIE-31 Overall Score at 1,3,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Number of Anti-epileptic Drugs Prescribed</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Engel and McHugh description</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>PINS Deep Brain Stimulator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep Brain Stimulator is on,continuous stimulation to the brain,</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PINS'Deep Brain Stimulator device</intervention_name>
    <description>deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time</description>
    <arm_group_label>PINS Deep Brain Stimulator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 12-60.

          -  having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance
             or to blood levels at upper end of the target range of which at least 2 have been
             tolerated at normal dose.

          -  at least 6 seizures per month.

          -  in good health except epilepsy.

          -  to with normal MMSE score

          -  patients or his(her) familys could understand this method and sign the informed
             consent 7）Patients with good compliance and could complete postoperative follow-up

        Exclusion Criteria:

          -  results of MRI remind epilepsy caused by intracranial space-occupying lesions.

          -  the vagus nerve lesion and damage

          -  tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma，mental
             disease，peptic ulcer，diabetes Type 1，bad health etc, and other surgical
             contraindication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luming Li</last_name>
    <role>Study Chair</role>
    <affiliation>study principal investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fumin Jia</last_name>
    <phone>+86 010-59361265</phone>
    <email>pins_medical@163.con</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luming Li</last_name>
    <phone>+86 010-60736388</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianguo Zhang, MD</last_name>
      <phone>010-67096611</phone>
      <email>Limuxin2011@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PINS</keyword>
  <keyword>Deep Brain Stimulator</keyword>
  <keyword>Refractory Epilepsy</keyword>
  <keyword>Anterior Thalamic Nucleus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

